1. Longitudinal characterization of nasopharyngeal colonization with Streptococcus pneumoniae in a South African birth cohort post 13-valent pneumococcal conjugate vaccine implementation
- Author
-
Mark P. Nicol, Felix S. Dube, Polite M. Nduru, Heather J. Zar, Jordache Ramjith, Nicole Wolter, Sugnet Gardner-Lubbe, and F. J. Lourens Robberts
- Subjects
Male ,0301 basic medicine ,Serotype ,medicine.medical_specialty ,030106 microbiology ,lcsh:Medicine ,Serogroup ,medicine.disease_cause ,Article ,Pneumococcal conjugate vaccine ,Pneumococcal Vaccines ,03 medical and health sciences ,0302 clinical medicine ,Nasopharynx ,Internal medicine ,Streptococcus pneumoniae ,medicine ,Humans ,Longitudinal Studies ,030212 general & internal medicine ,lcsh:Science ,Vaccines, Conjugate ,Multidisciplinary ,business.industry ,lcsh:R ,Infant ,Carriage ,Carrier State ,Cohort ,Nasopharyngeal colonization ,Female ,lcsh:Q ,Quellung reaction ,Birth cohort ,business ,medicine.drug - Abstract
Monitoring changes in pneumococcal carriage is key to understanding vaccination-induced shifts in the ecology of carriage and impact on health. We longitudinally investigated pneumococcal carriage dynamics in infants. Pneumococcal isolates were obtained from nasopharyngeal (NP) swabs collected 2-weekly from 137 infants enrolled from birth through their first year of life. Pneumococci were serotyped by sequetyping, confirmed by Quellung. Pneumococci were isolated from 54% (1809/3331) of infants. Median time to first acquisition was 63 days. Serotype-specific acquisition rates ranged from 0.01 to 0.88 events/child-year and did not differ between PCV13 and non-PCV13 serotypes (0.11 events/child-year [95% CI 0.07–0.18] vs. 0.11 events/child-year [95% CI 0.06–0.18]). There was no difference in carriage duration between individual PCV13 and non-PCV13 serotypes (40.6 days [95% CI 31.9–49.4] vs. 38.6 days [95% CI 35.1–42.1]), however cumulatively the duration of carriage of non-PCV13 serotypes was greater than PCV13 serotypes (141.2 days (95% CI 126.6–155.8) vs. 30.7 days (95% CI 22.3–39.0). Frequently carried PCV13 serotypes included 19F, 9V, 19A and 6A, while non-PCV13 serotypes included 15B/15C, 21, 10A, 16F, 35B, 9N and 15A. Despite high immunization coverage in our setting, PCV13 serotypes remain in circulation in this cohort, comprising 22% of isolates. Individual PCV13 serotypes were acquired, on average, at equivalent rate to non-PCV13 serotypes, and carried for a similar duration, although the most common non-PCV13 serotypes were more frequently acquired than PCV13 serotypes.
- Published
- 2018
- Full Text
- View/download PDF